The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease
Nathan AS, Sen S, Yeh RW. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opinion On Drug Safety 2017, 16: 561-572. PMID: 28387542, DOI: 10.1080/14740338.2017.1315101.Peer-Reviewed Original ResearchMeSH KeywordsBlood PlateletsCardiovascular DiseasesCoronary Artery DiseaseDecision MakingHemorrhageHumansPlatelet Aggregation InhibitorsRiskThrombosisConceptsAntiplatelet agentsCardiovascular diseaseVascular endotheliumSignificant bleeding riskMainstay of therapyAvailable antiplatelet agentsCoronary vascular endotheliumClinical prediction ruleAcute thrombotic eventsArterial cardiovascular diseaseAvailable antiplatelet therapyNormal healing responseOcclusive cardiovascular diseaseAntiplatelet therapyBleeding riskThrombotic eventsThrombotic riskArterial thrombiRisk scoreThrombus formationHealing responseDiseaseMajor causePrediction ruleHemostatic plug